www.fdanews.com/articles/92090-biogen-touts-ms-drug-as-cost-effective
Biogen Touts MS Drug as Cost Effective
April 16, 2007
Drug maker Biogen Idec Inc. said Friday a one-year study of its multiple sclerosis
drug Avonex shows it is more cost-effective than similar treatments.
BusinessWeek